Eribulin exerts its pharmacologic effects by binding to the plus ends of microtubules and suppressing microtubule growth, without affecting microtubule shortening, and by inducing the formation of ...
The FDA has accepted a supplemental new drug application (sNDA) seeking expanded indication for darolutamide (Nubeqa) for use in combination with androgen deprivation therapy (ADT) for the treatment ...